Research Topics
| Gregory GrabowskiSummaryAffiliation: Cincinnati Children's Hospital Medical Center Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Gaucher disease and other storage disordersGregory A Grabowski
Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229 3039, USA
Hematology Am Soc Hematol Educ Program 2012:13-8. 2012..Although perceived as rare, the availability of treatment and the impact of the LSDs on more common diseases require their integration into routine clinical practice...
Comparison of measures of marker informativeness for ancestry and admixture mappingLili Ding
Cincinnati Children s Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
BMC Genomics 12:622. 2011....
Temporal gene expression profiling reveals CEBPD as a candidate regulator of brain disease in prosaposin deficient miceYing Sun
Division of Human Genetics, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, MLC 4006, Cincinnati, OH, USA
BMC Neurosci 9:76. 2008..Extensive GSL storage occurs in various central nervous system regions in mammalian prosaposin deficiencies...
Multiple interactions between the alpha 2C- and beta1-adrenergic receptors influence heart failure survivalSharon L R Kardia
Department of Epidemiology, School of Public Health, University of Michigan, 109 Observatory St, Ann Arbor, MI 48109 2029, USA
BMC Med Genet 9:93. 2008..The purpose of this study was to investigate possible synergistic effects of polymorphisms of these two intronless genes (ADRB1 and ADRA2C, respectively) on the risk of death/transplant in heart failure patients...
Treatment perspectives for the lysosomal storage diseasesGregory A Grabowski
University of Cincinnati College of Medicine, Cincinnati Children s Hospital Medical Center, The Division of Human Genetics, Department of Pediatrics, Cincinnati, Ohio 45229 3039, USA
Expert Opin Emerg Drugs 13:197-211. 2008..This approach in Gaucher disease provided a prototype for the basic and clinical sciences, and the economic foundation for other ultra-orphan diseases...
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1Gregory A Grabowski
Cincinnati Children s Hospital Medical Center, Division of Human Genetics, Cincinnati, Ohio 45229 3039, USA
Genet Med 11:92-100. 2009..To determine whether enzyme therapy with imiglucerase/alglucerase demonstrates dose-response relationships with doses and disease parameters used in routine clinical practice for Gaucher disease type 1 patients...
Gaucher disease: lessons from a decade of therapyGregory A Grabowski
Division and Program in Human Genetics, Children's Hospital Research Foundation, Cincinnati, Ohio 45229-3039, USA
J Pediatr 144:S15-9. 2004
Global gene expression profile progression in Gaucher disease mouse modelsYou Hai Xu
The Division of Human Genetics, Cincinnati Children s Hospital Research Foundation, Cincinnati, OH 45229 3039, USA
BMC Genomics 12:20. 2011..The pathogenic pathways resulting from lipid laden macrophages (Gaucher cells) in visceral organs and their abnormal functions are obscure...
Perspectives on gene therapy for lysosomal storage diseases that affect hematopoiesisGregory A Grabowski
Division and Program in Human Genetics, Children s Hospital Medical Center, TCHRF 1042, 3333 Burnet Avenue, Cincinnati, OH 45229, USA
Curr Hematol Rep 2:356-62. 2003..These storage diseases provide the basis for continued development of gene therapy...
Delivery of lysosomal enzymes for therapeutic use: glucocerebrosidase as an exampleGregory A Grabowski
The Division and Programme in Human Genetics, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229 3039, USA
Expert Opin Drug Deliv 3:771-82. 2006..Similar results are being obtained in several other lysosomal storage diseases. Evolving gene and chaperone approaches provide alternative treatment strategies...
Specific saposin C deficiency: CNS impairment and acid beta-glucosidase effects in the mouseYing Sun
Division of Human Genetics, Cincinnati Children s Hospital Medical Center, Cincinnati, OH, USA
Hum Mol Genet 19:634-47. 2010..These results support the view that saposin C has multiple roles in glycosphingolipid (GSL) catabolism as well as a prominent function in CNS and axonal integrity independent of its role as an optimizer/stabilizer of GCase...
Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variantsYing Sun
Division and Program in Human Genetics, Children s Hospital Research Foundation, Cincinnati, OH 45229 3039, USA
J Lipid Res 46:2102-13. 2005..These models mimic a more severe Gaucher disease phenotype and could be useful for therapeutic intervention studies...
Saposin C: neuronal effect and CNS delivery by liposomesZhengtao Chu
Division and Program in Human Genetics, Children's Hospital Research Foundation, University of Cincinnati, Ohio 45229-3039, USA
Ann N Y Acad Sci 1053:237-46. 2005..These studies may yield a new therapeutic approach for neuron protection, preservation, and regeneration...
Neurological deficits and glycosphingolipid accumulation in saposin B deficient miceYing Sun
Division of Human Genetics, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229 3039, USA
Hum Mol Genet 17:2345-56. 2008..B-/- provide a useful model for understanding the contributions of this saposin to GSL metabolism and homeostasis...
Dependence of reversibility and progression of mouse neuronopathic Gaucher disease on acid beta-glucosidase residual activity levelsYou Hai Xu
The Divisions of Human Genetics, Cincinnati Children s Hospital Medical Center, 3333 Burnet Avenue, MLC 4006, Cincinnati, OH 45229 3039, USA
Mol Genet Metab 94:190-203. 2008..The persistent CNS deterioration, histologic abnormalities, and glucosylceramide storage in the CBE-treated D409V mice revealed a threshold level of GCase activity necessary for the prevention of progression of CNS involvement...
Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapyRichard J Wenstrup
Division of Human Genetics, Children s Hospital Research Foundation ML 4006, Cincinnati OH 45229 3039, USA
Blood 104:1253-7. 2004..Alendronate is a useful adjunctive therapy in combination with enzyme replacement therapy (ERT) for the treatment of GD-related osteopenia in adults, but it cannot be expected to improve focal lesions...
In vivo and ex vivo evaluation of L-type calcium channel blockers on acid beta-glucosidase in Gaucher disease mouse modelsYing Sun
The Division of Human Genetics, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, USA
PLoS ONE 4:e7320. 2009..These results show that LTCC blockers had the ex vivo effects of increasing GCase activity and protein in the mouse fibroblasts, but these effects did not translate into similar changes in vivo even at very high drug doses...
Neuronopathic Gaucher disease in the mouse: viable combined selective saposin C deficiency and mutant glucocerebrosidase (V394L) mice with glucosylsphingosine and glucosylceramide accumulation and progressive neurological deficitsYing Sun
The Division of Human Genetics, Cincinnati Children s Hospital Medical Center, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229 3039, USA
Hum Mol Genet 19:1088-97. 2010....
Combined saposin C and D deficiencies in mice lead to a neuronopathic phenotype, glucosylceramide and alpha-hydroxy ceramide accumulation, and altered prosaposin traffickingYing Sun
Division of Human Genetics, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 45229, USA
Hum Mol Genet 16:957-71. 2007..This CD null mouse model provides a tool to explore the in vivo functional interactions of saposins in GSL metabolism and lysosomal storage diseases, and prosaposin's physiological effects...
Prosaposin: threshold rescue and analysis of the "neuritogenic" region in transgenic miceYing Sun
The Division and Program in Human Genetics, Children s Hospital Research Foundation, Cincinnati, OH 45229 3039, USA
Mol Genet Metab 76:271-86. 2002..These studies also show in vivo localization of the GCase activation region to the carboxy terminal half of saposin C and the lack of a significant gross trophic effect of saposin C on CNS organization in vivo...
Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher diseaseYou Hai Xu
Divisions of Human Genetics and Pathology, Cincinnati Children s Hospital Research Foundation, 3333 Burnet Avenue, Cincinnati, Ohio 45229 3039, USA
Am J Pathol 163:2093-101. 2003..These GCase-deficient mice provide tools for gaining insight into the pathophysiology of Gaucher disease and developing improved therapies...
Comparative therapeutic effects of velaglucerase alfa and imiglucerase in a Gaucher disease mouse modelYou Hai Xu
Division of Human Genetics, Cincinnati Children s Hospital Research Foundation, Cincinnati, Ohio, USA
PLoS ONE 5:e10750. 2010..The responses of GC levels and storage cell numbers in Vela- and Imig-treated Gaucher mice at various doses provide a backdrop for clinical applications and decisions...
Analyses of temporal regulatory elements of the prosaposin gene in transgenic miceYing Sun
The Division and Program in Human Genetics, Children's Hospital Medical Center, 3333 Burnet Avenue, PAV 3-52, Cincinnati, OH 45229-3039, USA
Biochem J 370:557-66. 2003..Additional regulatory elements outside the 5' region of the 2400 bp promoter fragment appear to be essential for the physiological control of the prosaposin locus...
Ex vivo localization of the mouse saposin C activation region for acid beta-glucosidaseXiaoyang Qi
The Division of Human Genetics, Children's Hospital Research Foundation and Department of Pediatrics, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA
Mol Genet Metab 76:189-200. 2002..These results also show that the enzymatic activation domain is located at carboxyl-terminal half of saposin C and functions only in the context of the general saposin structure...
Conditional expression of human acid beta-glucosidase improves the visceral phenotype in a Gaucher disease mouse modelYing Sun
Division of Human Genetics, Children s Hospital Research Foundation and University of Cincinnati College of Medicine, Department of Pediatrics, Cincinnati, OH 45229 3039, USA
J Lipid Res 47:2161-70. 2006..This study demonstrates that conditionally expressed hGCase supplemented the existing mutant mouse GCase to control visceral substrate accumulation in vivo...
The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapyHong Du
Division and Program in Human Genetics, Cincinnati Children s Hospital Research Foundation, Cincinnati, OH 45229 3039, USA
Am J Hum Genet 77:1061-74. 2005....
Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutationsBenjamin Liou
Division and Program in Human Genetics, Children's Hospital Research Foundation, Cincinnati, OH 45229, USA
J Biol Chem 281:4242-53. 2006..g. Val --> Leu). These results provide initial studies for the engineering of variant GCases and, potentially, molecular chaperones for therapeutic use...
Gaucher disease: in vivo evidence for allele dose leading to neuronopathic and nonneuronopathic phenotypesHuiquan Zhao
Division and Program in Human Genetics, Children's Hospital Research Foundation, Cincinnati, Ohio, USA
Am J Med Genet A 116:52-6. 2003..Designation of genotype associations with specific phenotypes must be assessed with this perspective...
Phenotype, diagnosis, and treatment of Gaucher's diseaseGregory A Grabowski
Cincinnati Children s Hospital Medical Center, Division of Human Genetics, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, USA
Lancet 372:1263-71. 2008..These developments are novel, clinically important, advancements for patients with other lysosomal storage diseases and genetic diseases...
Enzyme therapy of gaucher disease: clinical and biochemical changes during production of and tolerization for neutralizing antibodiesHuiquan Zhao
Division and Program in Human Genetics, Cincinnati Children's Research Foundation, OH 45229, USA
Blood Cells Mol Dis 30:90-6. 2003..The persistence of minimal amounts of in vitro neutralizing antibodies does not interfere with the therapeutic effectiveness. Chitotriosidase is not a sensitive marker for the severity of disease or disease progression...
Enzyme reconstitution/replacement therapy for lysosomal storage diseasesT Andrew Burrow
Division of Human Genetics, Cincinnati Children s Hospital Medical Center and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, Ohio 45229 3039, USA
Curr Opin Pediatr 19:628-35. 2007....
Participation of asparagine 370 and glutamine 235 in the catalysis by acid beta-glucosidase: the enzyme deficient in Gaucher diseaseBenjamin Liou
The A Graeme Mitchell Chair in Human Genetics, Division and Program in Human Genetics, Children s Hospital Medical Center, 3333 Burnet Avenue, ML 4006, Cincinnati, OH 45229 3039, USA
Mol Genet Metab 97:65-74. 2009..This study provides insight into the function of these residues in acid beta-glucosidase active site function...
Gaucher disease: progressive mesenteric and mediastinal lymphadenopathy despite enzyme therapyT Andrew Burrow
Division of Human Genetics, Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio 45229, USA
J Pediatr 150:202-6. 2007..These complications are unique, indicating poorly accessible, differentially responsive compartments in patients with Gaucher's disease who are receiving enzyme therapy...
Lysosomal acid lipase deficiency: correction of lipid storage by adenovirus-mediated gene transfer in miceHong Du
Division of Human Genetics, Cincinnati Children s Hospital Research Foundation, Cincinnati, OH 45229, USA
Hum Gene Ther 13:1361-72. 2002..These studies provide the basis for the use of gene therapy, in the form of gene transfer via intravenously administered adenovirus, to correct deficiency states, such as WD and CESD, and histopathology of a variety of tissues...
Reduction of atherosclerotic plaques by lysosomal acid lipase supplementationHong Du
Division and Program in Human Genetics, Children's Hospital Research Foundation, Cincinnati, OH 45229, USA
Arterioscler Thromb Vasc Biol 24:147-54. 2004..CONCLUSIONS: These results support the potential utility of lysosomal acid lipase supplementation for the treatment of atherosclerosis, a leading cause of mortality and morbidity in Westernized nations...
Saposin C is required for normal resistance of acid beta-glucosidase to proteolytic degradationYing Sun
Division and Program in Human Genetics, Children s Hospital Research Foundation, Cincinnati, Ohio 45229 3039, USA
J Biol Chem 278:31918-23. 2003..Thus, diminished in vivo GCase activity would be greater than expected only from the lack of GCase activation by saposin C. These results indicate a new property for saposin C, an anti-proteolytic protective function toward GCase...
Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statementsGregory A Grabowski
Division and Program in Human Genetics, Children s Hospital Research Foundation, Cincinnati, OH 45229 3039, USA
Eur J Pediatr 163:58-66. 2004..CONCLUSION: A thorough approach to baseline assessment will improve the understanding of childhood Gaucher disease, optimizing management to minimize impairment of growth and development and prevent irreversible symptoms...
Recent clinical progress in Gaucher diseaseGregory A Grabowski
The Children s Hospital Research Foundation, Cincinnati Children s Hospital Medical Center, and the Department of Pediatrics of the University of Cincinnati, Cincinnati, Ohio 45229 3039, USA
Curr Opin Pediatr 17:519-24. 2005..Major clinical advances in Gaucher disease focus on detection, prediction and treatment of variant phenotypes...
Wolman disease/cholesteryl ester storage disease: efficacy of plant-produced human lysosomal acid lipase in miceHong Du
Division and Program in Human Genetics, Cincinnati Children s Hospital Research Foundation, Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
J Lipid Res 49:1646-57. 2008..These studies demonstrate the feasibility of using plant-expressed, recombinant hLAL for the enzyme therapy of human WD/CESD with general implications for other lysosomal storage diseases...
Enzyme therapy for lysosomal storage disease: principles, practice, and prospectsGregory A Grabowski
The Division and Program in Human Genetics, Cincinnati Children s Hospital Research Foundation, Cincinnati, Ohio, 45229 3039, USA
Annu Rev Genomics Hum Genet 4:403-36. 2003..The principles, progress, and practice in these diseases provide prototypes for expansion of enzyme therapy to a growing set of these diseases...
Multi-system disorders of glycosphingolipid and ganglioside metabolismYou Hai Xu
Division of Human Genetics, Cincinnati Children s Hospital Medical Center and the Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH 45229 3039, USA
J Lipid Res 51:1643-75. 2010..These are the focus of this review...
Translation modulation of acid beta-glucosidase in HepG2 cells: participation of the PKC pathwayYou-Hai Xu
Division of Human Genetics, The Children's Hospital Research Foundation, Cincinnati, OH 45229-3039, USA
Mol Genet Metab 84:252-64. 2005..These findings indicate potential broader impacts of the TCP/PKC system on expression of this and other genes of therapeutic interest...
Phospholipid membrane interactions of saposin C: in situ atomic force microscopic studyHong Xing You
Department of Cell Biology, Neurobiology, and Anatomy, University of Cincinnati College of Medicine, Ohio 45267 0521, USA
Biophys J 84:2043-57. 2003..This study provides an approach to investigate the structure-function aspects of Sap C interaction with phospholipid membranes, with insights into the mechanism(s) of Sap C-membrane interaction...
Phospholipid vesicle fusion induced by saposin CYing Wang
Division and Program in Human Genetics, Children's Hospital Research Foundation, 3333 Burnet Avenue, Cincinnati, OH 45229-3039, USA
Arch Biochem Biophys 415:43-53. 2003..Addition of selected saposin C peptides prior to intact saposin C in reaction mixtures abolished the liposomal fusion. These results indicated that saposin-membrane and saposin-saposin interactions are needed for the fusion process...
Phenotypic and genotypic heterogeneity in Gaucher disease type 1: a comparison between Brazil and the rest of the worldElisa Sobreira
FCM Santa Casa de São Paulo, Sao Paulo, SP, Brazil
Mol Genet Metab 90:81-6. 2007..The findings also emphasize the need for caution in making generalizations about Gaucher disease across demographic groups...
A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher diseaseKerry Anne McEachern
Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701 9322, USA
Mol Genet Metab 91:259-67. 2007..These data indicate that substrate inhibition therapy with Genz-112638 represents a viable alternate approach to enzyme therapy to treat the visceral pathology in Gaucher disease...
Paediatric non-neuronopathic Gaucher disease: recommendations for treatment and monitoringAntonio Baldellou
Unidad de Enfermedades Metabolicas, Hospital Infantil Miguel Servet, Po Isabel la Católica, 350009 Zaragoza, Spain
Eur J Pediatr 163:67-75. 2004..CONCLUSION: Through comprehensive and serial monitoring, ultimately, a therapeutic dose of enzyme therapy that achieves sustained benefits can be found for each child with non-neuronpathic Gaucher disease...
AAV8-mediated expression of glucocerebrosidase ameliorates the storage pathology in the visceral organs of a mouse model of Gaucher diseaseKerry Anne McEachern
Genzyme Corporation, 31 New York Avenue, Framingham, MA 01701-9322, USA
J Gene Med 8:719-29. 2006....
Editing of CD1d-bound lipid antigens by endosomal lipid transfer proteinsDapeng Zhou
Department of Pathology, University of Chicago, Chicago, IL 60637, USA
Science 303:523-7. 2004..LTPs constitute a previously unknown link between lipid metabolism and immunity and are likely to exert a profound influence on the repertoire of self, tumor, and microbial lipid antigens...
Vitreous opacities and retinal vascular abnormalities in Gaucher diseaseEric M Shrier
Department of Ophthalmology and Visual Sciences, University of Louisville School of Medicine, 301 E. Muhammad Ali Boulevard, Louisville, KY 40202, USA
Arch Ophthalmol 122:1395-8. 2004
Therapeutic goals in the treatment of Gaucher diseaseGregory M Pastores
Neurology in Pediatrics, Neurgenetics Unit, Department of Neurology, New York University School of Medicine, NY, USA
Semin Hematol 41:4-14. 2004..Here we establish goals of treatment in Gaucher disease and propose a comprehensive schedule of monitoring of all relevant aspects to confirm the achievement, maintenance, and continuity of the therapeutic response...
Guidance on the use of miglustat for treating patients with type 1 Gaucher diseaseNeal J Weinreb
University Research Foundation for Lysosomal Storage Diseases and Northwest Oncology Hematology Associates PA, Coral Springs, Florida
Am J Hematol 80:223-9. 2005....
Prevalence of type 1 Gaucher disease in the United StatesNeal J Weinreb
Arch Intern Med 168:326-7; author reply 327-8. 2008
Apolipoprotein E-deficient lipoproteins induce foam cell formation by downregulation of lysosomal hydrolases in macrophagesDongfang Wu
Department of Cardiovascular Biology, Meharry Medical College, Nashville, TN 37208, USA
J Lipid Res 48:2571-8. 2007....
Characterization of neuronopathic Gaucher disease among ethnic PolesAnna Tylki-Szymanska
Department of Metabolic Diseases, The Children s Memorial Health Institute, Warsaw, Poland
Genet Med 8:8-15. 2006..Here, the clinical and molecular findings of the subacute neuronopathic variant are delineated among ethnic Poles...
Research Grants
- STUDIES OF GAUCHER DISEASE: A PROTOTYPE LIPIDOSISGregory A Grabowski; Fiscal Year: 2010..This approach offers the potential for more complete therapy, including the CNS, as well as less expensive and more convenient therapy for this disease as prototype for this class of disorders. ..
- INBORN ERRORS OF SPHINGOLIPID CATABOLISMGregory Grabowski; Fiscal Year: 2004..abstract_text> ..
- Studies of Prosaposin's Physiologic RoleGregory Grabowski; Fiscal Year: 2003..These studies have implications for GSL metabolism, and lysosomal storage disease phenotypic expression and therapy. ..
- STUDIES OF GAUCHER DISEASE: A PROTOTYPE LIPIDOSISGregory Grabowski; Fiscal Year: 2005..These studies should provide insights into the pathophysiology and therapy of GD, and to over 20 glycolipid storage diseases that depend on the GCS synthetic and GCase degradative pathwavs. ..
- Studies of Prosaposin's Physiologic RoleGregory Grabowski; Fiscal Year: 2006..These studies have implications for GSL metabolism, and lysosomal storage disease phenotypic expression and therapy. ..
- STUDIES OF GAUCHER DISEASE: A PROTOTYPE LIPIDOSISGregory A Grabowski; Fiscal Year: 2010....
- STUDIES OF GAUCHER DISEASE: A PROTOTYPE LIPIDOSISGregory Grabowski; Fiscal Year: 2009..This approach offers the potential for more complete therapy, including the CNS, as well as less expensive and more convenient therapy for this disease as prototype for this class of disorders. ..
- STUDIES OF GAUCHER DISEASE: A PROTOTYPE LIPIDOSISGregory A Grabowski; Fiscal Year: 2010....
- STUDIES OF GAUCHER DISEASE: A PROTOTYPE LIPIDOSISGregory Grabowski; Fiscal Year: 2009....
- STUDIES OF GAUCHER DISEASE: A PROTOTYPE LIPIDOSISGregory Grabowski; Fiscal Year: 2009....
- STUDIES OF GAUCHER DISEASE: A PROTOTYPE LIPIDOSISGregory Grabowski; Fiscal Year: 2007....
- Studies of Prosaposin's Physiologic RoleGregory Grabowski; Fiscal Year: 2007..These studies have implications for GSL metabolism, and lysosomal storage disease phenotypic expression and therapy. ..
- Use of Hammerhead Ribozymes in Murine Models of OlGregory Grabowski; Fiscal Year: 2007....
- PROSAPOSINS PHYSIOLOGIC ROLEGregory Grabowski; Fiscal Year: 2001..The results of these experiments have major import for understanding CNS development, nerve regeneration, GSL metabolism and the pathophysiology of GSL inborn errors of metabolism. ..
- GAUCHER DISEASEGregory Grabowski; Fiscal Year: 2000..The results of these investigations should provide a deeper understanding of beta-GIc's function and the pathophysiology of GD as a basis for improved therapies for this and other inborn errors of metabolism. ..
- STUDIES OF GAUCHER DISEASE: A PROTOTYPE LIPIDOSISGregory Grabowski; Fiscal Year: 1993....
